true FY 0001701478

 0001701478

 2023-01-01
 2023-12-31

 0001701478

 2023-06-30

 0001701478

 2024-04-23

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM
 10-K/A

 Amendment
No. 1

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended December 31, 2023

 or

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from __________ to __________

 Commission
file number: 001-41705

 Azitra,
Inc.

 (Exact
name of registrant as specified in its charter)

 Delaware

 46-4478536

 (State
 or Other Jurisdiction

 of
 Incorporation or Organization)

 (I.R.S.
 Employer

 Identification
 Number)

Business Park Drive

 Branford,
 CT 06405

 (Address
of principal executive offices)

 (203) 646-6446

 (Registrant's
telephone number, including area code)

 Securities
registered pursuant to Section 12(b) of the Act:

 Title
 of each class

 Trading
 Symbol(s)

 Name
 of each exchange on which registered

 Common
 stock: Par value $0.0001

 AZTR

 NYSE
 American

 Securities
registered pursuant to Section 12(g) of the Act:

 None

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes No

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

 State
the aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's
most recently completed second fiscal quarter: $ 20,042,404.

 The
number of shares of the registrant's common stock outstanding as of April 23, 2024 was 28,804,643.

 DOCUMENTS
INCORPORATED BY REFERENCE

 None.

 Audit Firm ID

 Auditor Name

 Auditor Location

 GRASSI & CO., CPAs, P.C.

 Jericho, New York

 TABLE
OF CONTENTS

 Page

 PART
 III

 Item
 10.

 Directors, Executive Officers and Corporate Governance

 Item
 11.

 Executive Compensation

 Item
 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item
 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item
 14.

 Principal Accountant Fees and Services

 PART
 IV

 Item
 15.

 Exhibits and Financial Statement Schedules

 Item
 16.

 Form 10-K Summary

 Signatures

 i

 EXPLANATORY
NOTE

 This
Amendment No. 1 (this "Amendment") amends the Annual Report on Form 10-K for the year ended December 31, 2023 of Azitra,
Inc. filed with the Securities and Exchange Commission (the "SEC") on March 15, 2024 (the "Original Form 10-K").
The purpose of this Amendment is to amend Part III, Items 10 through 14 of the Original Form 10-K to include information previously omitted
from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K. Accordingly, Part III of the Original Form 10-K is
hereby amended and restated as set forth below and the reference on the cover page of the Original Form 10-K to the incorporation by
reference of our definitive proxy statement into Part III of the Original Form 10-K is hereby deleted.

 In
addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") new certifications
by our principal executive officer and principal financial officer are filed as exhibits to this Amendment under Item 15 of Part IV hereof,
which has been amended to reflect the filing of these new certifications. Because no financial statements have been included in this
Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs
3, 4, and 5 of the certifications have been omitted.

 Except
as described above, no other changes have been made to the Original Form 10-K. The Original Form 10-K continues to speak as of the date
of the Original Form 10-K, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent
to the filing of the Original Form 10-K other than as expressly indicated in this Amendment. In this Amendment, unless the context indicates
otherwise, the terms "Company," "we," "us," and "our" refer to Azitra, Inc. Other defined
terms used in this Amendment but not defined herein shall have the meaning specified for such terms in the Original Form 10-K.

 ii

 CAUTIONARY
NOTICE

 This
Amendment contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include our expectations, beliefs, intentions
and strategies regarding the future. These and other factors that may affect our financial results are discussed more fully in "Risk
Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included
in the Original Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time
to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed
in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in our forward-looking
statements. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee
that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will
be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking
statements. We caution readers not to place undue reliance on any forward-looking statements. We do not undertake, and specifically disclaim
any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur, and we urge readers
to review and consider disclosures we make in this and other reports that discuss factors germane to our business. See in particular
our reports on Forms 10-K, 10-Q, and 8-K subsequently filed from time to time with the Securities and Exchange Commission.

 Except
as otherwise indicated, all share and share price in this report gives effect to a forward stock split effected on May 17, 2023 at a
ratio of one for 7.1 for one.

 iii

 PART
III

 Item
10. Directors, Executive Officers and Corporate Governance

 Executive
Officers and Directors

 The
following table sets forth the names, ages and positions of our current executive officers and directors.

 Name

 Age

 Position

 D. Salva

 President,
 Chief Executive Officer and Director

 Norman
 Staskey

 Chief
 Financial Officer

 Travis
 Whitfill

 Chief
 Operating Officer and Director

 Andrew
 McClary, MD

 Independent
 Director

 Barbara
 Ryan

 Independent
 Director

 John
 Schroer

 Independent
 Director

 Information
about our Executive Officers and Directors

D. Salva has served as our president and chief executive officer and a member of our Board since April 2021. Mr. Salva has over
15 years of experience in senior leadership roles in the biotechnology and pharmaceutical industries. Mr. Salva served as president and
chief executive officer of Complexa, Inc., an inflammation and fibrosis focused biopharmaceutical company, from May 2018 to August 2020.
From February 2011 to November 2016, Mr. Salva served as a co-founder and vice president of operations of Acerta Pharma B.V., Inc, a
cancer and autoimmune focused biopharmaceutical company. Mr. Salva serves as a director of Vincerx Pharma, Inc. (Nasdaq: VINC). Prior
to his operating roles, Mr. Salva served in various senior positions in the venture capital and investment banking industries focusing
on healthcare, biotechnology and pharmaceuticals companies. Mr. Salva received a B.A. from Brown University and an MSc in economics and
philosophy from the London School of Economics. We believe that Mr. Salva's experience as a senior executive, venture capitalist
and investment banker in the biotech and pharmaceutical industries qualifies him to serve on our Board.

 Norman
Staskey has served as our chief financial officer since October 2022. Since May 15, 2021, Mr. Staskey has also served as a senior
director of Danforth Advisors, a national consulting firm providing financial, accounting and reporting services to the life science
industry. From September 2014 to May 2021, Mr. Staskey was employed by EY (formally Ernst & Young), most recently as a managing director
in EY's Financial Accounting and Advisory services practice.

 Travis
Whitfill is a co-founder of Azitra and has served on our Board since inception. Mr. Whitfill has served in various roles at Azitra,
including chief scientific officer from January 2014 to September 2019 and director of advanced technology since September 2019, and
as chief operating officer since June 2023. Mr. Whitfill served as a partner at Bios Equity Partners, LP, a biotechnology-focused venture
capital firm, from October 2015 to June 2023 and a senior analyst at Bios Research from September 2014 to June 2023. He has also served
as an associate research scientist and assistant professor adjunct at Yale University from July 2016 to March 2022 and since March 2022,
respectively, with appointments in the Departments of Pediatrics and Emergency Medicine. Mr. Whitfill has served on the board of directors
of IN8Bio, Inc. (Nasdaq: INAB) since March 2018, 410 Medical from September 2017 to July 2019 and SIRPant Immunotherapeutics from September
2021 to June 2023. Mr. Whitfill has led numerous grant-funded projects, holds several patents and has co-authored over 60 publications.
Mr. Whitfill received a B.S. from Dallas Baptist University, an MPH from Yale University and an MPhil from University College London.
We believe that Mr. Whitfill's strong background in entrepreneurship and in the biotech and healthcare industries qualifies him
to serve on our Board.

 Andrew
McClary, MD has served as a member of our Board since March 2019. Dr. McClary is the founding general partner at KdT Ventures
LP, a biotechnology focused venture firm founded in 2017. At KdT, Dr. McClary invests in companies leveraging the intersection of the
physical sciences and engineering, both computational and biochemical. In addition to leading KdT's investment in Azitra, Dr. McClary
has also led KdT's investments in PathAI, Dyno Therapeutics, Solugen, Terray Therapeutics, STRM Therapeutics, Elegen, and Checkerspot.
Prior to KdT, Dr. McClary served on faculty as a Pathologist at Stanford University and was an early employee at Included Health (formerly
known as Grand Rounds), where he was the physician lead for the Data Science and Analytics team. Dr. McClary received his M.D. from Tulane
University, where he has held prior academic appointments and was an HHMI/NIH Fellow, and his Sc. B. in Biochemistry and Molecular Biology
from Brown University. We believe that Dr. McClary's medical and scientific expertise as a physician-scientist coupled with his
experience working in the venture capital industry qualifies him to serve on our Board.

 Barbara
Ryan has served as a member of our Board since June 2023. Ms. Ryan founded Barbara Ryan Advisors, a capital markets and communications
firm, in 2012 following a more than 30-year career on Wall Street as a sell-side research analyst covering the U.S. pharmaceutical industry.
Ms. Ryan has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis and corporate strategy
across a broad range of life sciences companies. Ms. Ryan worked on several of the industry's largest M&A transactions, including
Shire's defense versus a hostile takeover attempt by Abbvie, Shire's takeover of Baxalta, Allergan's defense against
Valeant and Perrigo's defense versus Mylan Ms. Ryan served as an executive team member and on the disclosure committee for Radius
Health from January 2014 to December 2017. Previously, Ms. Ryan was a managing director at Deutsche Bank/Alex Brown and head of the company's
pharmaceutical research team for 19 years and began her research career covering the pharmaceutical industry at Bear Stearns in 1982.
Ms. Ryan currently serves as a director on the board of MiNK Therapeutics, Inc. (Nasdaq: INKT), where she chairs the audit committee,
INVO Bioscience, Inc, (Nasdaq: INVO), Invidior, PLC (LON:INDV) and The Red Door Community (formerly Gilda's Club NYC), a non-profit
organization. Ms. Ryan is the founder of Fabulous Pharma Females, a non-profit whose mission is to advance women in the biopharma industry,
is a member of the editorial advisory board of Pharmaceutical Executive Magazine, a faculty member of the GLG Institute and a member
of the Prix Galien executive advisory board. We believe that Ms. Ryan is qualified to serve as a member of our Board because of her experience
and knowledge of corporate finance, mergers and acquisitions, corporate governance, as well as other operational, financial and accounting
matters gained as a past and present executive officer and/or director of other public and private companies.

 John
Schroer has served as a member of our Board since June 2023. Mr. Schroer has served as chief financial officer of Alumis, Inc.,
a privately held biotechnology company developing precision immunology therapies, since March 2022. Mr. Schroer was chief financial officer
of Arsenal Biosciences, Inc., a privately held biotechnology company developing programmable cell therapy for solid tumors, from February
2021 to February 2022. Mr. Schroer was chief financial officer of Translate Bio, Inc., a biotechnology company developing mRNA therapeutics
and vaccines acquired by Sanofi in September 2021 for $3.2 billion, from May 2018 to December 2020. Previously, Mr. Schroer was Sector
Head – Global Health Care for Allianz Global Investors, an international asset management firm, from January 2014 to May 2018.
Mr. Schroer received his B.S. and M.B.A from the University of Wisconsin – Madison. We believe that Mr. Schroer's strong
background holding leadership positions in the biotechnology industry and almost 30 years of investing in the life sciences sector qualifies
him to serve on our Board.

 Family
Relationships

 There
are no family relationships among any of our executive officers or directors.

 Corporate
Governance

 Audit
Committee

 Our
audit committee consists of John Schroer, Andrew McClary and Barbara Ryan, with Mr. Schroer serving as chairperson. Our Board has determined
that each member meets the independence requirements of the Sarbanes-Oxley Act, Rule 10A-3 under the Exchange Act and the applicable
listing standards of the NYSE American. Each member of our audit committee can read and understand fundamental financial statements in
accordance with the SEC and NYSE American audit committee requirements. In arriving at this determination, the Board has examined each
audit committee member's scope of experience and the nature of their prior and/or current employment.

 Process
for Stockholders to Send Communications to our Board of Directors

 Because
we have always maintained open channels of communication with our stockholders, we do not have a formal policy that provides a process
for stockholders to send communications to our Board. However, if a stockholder would like to send a communication to our Board, please
address the letter to the attention of our corporate secretary, Travis Whitfill, and it will be distributed to each director.

 Section
16(A) Beneficial Ownership Reporting Compliance

 Rules
adopted by the SEC under Section 16(a) of the Exchange Act require our officers and directors, and persons who own more than 10% of the
issued and outstanding shares of our equity securities, to file reports of their ownership, and changes in ownership, of such securities
with the SEC on Forms 3, 4 or 5, as appropriate. Such persons are required by the regulations of the SEC to furnish us with copies of
all forms they file pursuant to Section 16(a).

 Based
solely upon a review of Forms 3, 4 and 5 and amendments thereto furnished to us during our most recent fiscal year, and any written representations
provided to us, we believe that all of the officers, directors, and owners of more than 10% of the outstanding shares of our common stock
complied with Section 16(a) of the Exchange Act for the year ended December 31, 2023.

 Code
of Ethics

 We
have adopted a Code of Ethics applicable to all of our employees, executive officers and directors. The Code of Ethics is available on
our website at www.azitrainc.com. The audit committee of our Board is responsible for overseeing the Code of Ethics and must approve
any waivers of the Code of Ethics for employees, executive officers and directors. In addition, we have posted on our website all disclosures
that are required by law or the listing standards of the applicable stock exchange concerning any amendments to, or waivers from, any
provision of the Code of Ethics.

 Item
11. Executive Compensation

 Summary
Compensation Table

 The
following table sets forth the compensation awarded to or earned by our chief executive officer and our two other highest paid executive
officers for the years ended December 31, 2023 and 2022. In reviewing the table, please note that:

 D. Salva was appointed to serve as our president and chief executive officer in April 2021;

 Norman
 Staskey was appointed to serve as our chief financial officer in October 2022; and

 Travis
 Whitfill was appointed to serve as our chief operating officer in June 2023.

 Year

 Salary ($)

 Bonus ($)

 Option Awards $ (1)

 All Other Compensation (2)

 Total

 Francisco D. Salva,

 2023

 $
 420,000

 $
 —

 $
 —

 $
 7,030

 $
 427,030

 Pres. and CEO

 2022

 $
 403,846

 $
 —

 $
 —

 $

 $
 404,048

 Norman Staskey,

 2023

 $
 —

 $
 —

 $
 20,700

 $
 314,025

 $
 334,725

 CFO

 2022

 $
 —

 $
 —

 $
 —

 $
 63,200

 $
 63,200

 Travis Whitfill,

 2023

 $
 158,846

 $
 —

 $
 20,700

 $
 2,767

 $
 182,313

 COO

 2022

 $
 —

 $
 —

 $
 —

 $
 10,050

 $
 10,050

 (1)

 The
 dollar amounts in the Option Awards columns above reflect the values of options as of the grant date for the years ended December
 31, 2023 and 2022, in accordance with ASC 718, Compensation-Stock Compensation ("ASC 718") and, therefore, do
 not necessarily reflect actual benefits received by the individuals. Assumptions used in the calculation of these amounts are included
 in Note 11 to our audited financial statements.

 (2)

 All
 other compensation includes commuter benefits, vacation payouts, relocation reimbursements, 401K match contributions, and life insurance
 premiums, plus consulting fees paid for Mr. Staskey's services as chief financial officer and consulting fees paid to Mr. Whitfill
 prior to his appointment as chief operating officer.

 Narrative
Disclosure to Officer Compensation Table

 All
of our current named executive officers are at-will employees and set forth below is a summary of the current terms of their compensatory
arrangements.

D. Salva

 We
have entered into an executive employment agreement dated April 22, 2021 with Mr. Salva, pursuant to which Mr. Salva serves as our president
and chief executive officer. We have agreed to pay Mr. Salva an annual base salary of $420,000 under the agreement. Mr. Salva is also
eligible to receive a bonus of up to 35% of his base salary based on performance parameters set by our Board. Mr. Salva's executive
employment agreement entitles him to participate in health insurance and other benefits, at our expense, made available to other executive
officers. In the event of Mr. Salva's termination by us without cause or his resignation for good reason, as such terms are defined
in the executive employment agreement, Mr. Salva will be entitled to the continuation of his base salary and health insurance coverage
for a period of 12 months and a prorated amount of his annual bonus for the year in which the termination occurred, subject to the achievement
of applicable performance targets. Mr. Salva's executive employment agreement is an "at will" agreement subject to
termination by either party at any time and for any reason, subject to certain notice requirements. The agreement contains customary
provisions relating to intellectual property assignment, confidentiality and indemnification.

 In
connection with our execution of the executive employment agreement, we granted to Mr. Salva an option to purchase up to 465,760 shares
of our common stock at an exercise price of $1.56 per share under the 2016 Plan. The options vest and become exercisable as follows:
80% of the options, or options to purchase 372,608 shares of our common stock, are subject to time-based vesting, with options to purchase
93,152 shares (25%) vesting on the first anniversary of the grant and options to purchase 279,456 shares (75%) vesting in equal monthly
installments over the 36 months following the first anniversary; 20% of the options, or options to purchase 13,120 shares of our common
stock, shall vest upon patient dosing in the first in-human clinical trial of ATR-12 or a substitute live biotherapeutic product, as
determined by our Board in its reasonable discretion. The options expire on the ten-year anniversary of the date of grant.

 Norman
Staskey

 Mr.
Staskey serves as our chief financial officer pursuant to a Consulting Agreement dated October 12, 2002 between us and Danforth Advisors,
LLC. Pursuant to the Consulting Agreement, Danforth Advisors provides to us certain strategic and financial advice and support services,
including Mr. Staskey's services as chief financial officer, at hourly rates between $135 and $575 per hour, depending on the level
of service and the seniority of the service provider. The Consulting Agreement is subject to termination by either party on 30 days written
notice and contains customary provisions relating to intellectual property assignment, confidentiality and indemnification.

 On
September 8, 2023, we granted to Mr. Staskey an option to purchase up to 10,000 shares of our common stock at an exercise price of $2.07
per share under the 2016 Plan. The options are subject to time-based vesting, with options to purchase 2,500 shares (25%) vesting on
the first anniversary of the grant and options to purchase 7,500 shares (75%) vesting in equal monthly installments over the 36 months
following the first anniversary; The options expire on the ten-year anniversary of the date of grant.

 Travis
Whitfill

 We
have entered into an executive employment agreement dated July 5, 2023 with Mr. Whitfill, pursuant to which Mr. Whitfill serves as our
chief operating officer. We have agreed to pay Mr. Whitfill an annual base salary of $350,000 under the agreement. Mr. Whitfill is also
eligible to receive a bonus of up to 30% of his base salary based on performance parameters set by our Board. Mr. Whitfill's executive
employment agreement entitles him to participate in health insurance and other benefits, at our expense, made available to other executive
officers. In the event of Mr. Whitfill's termination by us for any reason other than cause or his incapacity, as such terms are
defined in the executive employment agreement, Mr. Whitfill will be entitled to the continuation of his base salary for a period of six
months and, if unpaid at the time of termination, his annual bonus for the year prior to the year in which the termination occurred.
Mr. Whitfill's executive employment agreement is an "at will" agreement subject to termination by either party at any
time and for any reason, subject to certain notice requirements. The agreement contains customary provisions relating to intellectual
property assignment, confidentiality and indemnification.

 On
September 8, 2023, we granted to Mr. Whitfill an option to purchase up to 10,000 shares of our common stock at an exercise price of $2.07
per share under the 2016 Plan. The options are subject to time-based vesting, with options to purchase 2,500 shares (25%) vesting on
the first anniversary of the grant and options to purchase 7,500 shares (75%) vesting in equal monthly installments over the 36 months
following the first anniversary; The options expire on the ten-year anniversary of the date of grant.

 Outstanding
Equity Awards at December 31, 2023

 Set
forth below is information concerning the equity awards held by our named executive officers as of December 31, 2023.

 Option Awards

 Name

 Number of Securities Underlying Unexercised Options (#) Exercisable

 Number of Securities Underlying Unexercised Options (#) Unexercisable

 Option Exercise Price ($)

 Option Expiration Date

 Francisco Salva

 248,407

 124,200 1

 $
 1.70

 06/29/2031

 93,152 2

 $
 1.70

 06/29/2031

 Norm Staskey

 9,167 3

 $
 2.07

 09/08/2033

 Travis Whitfill

 55,785

 $
.48

 01/01/2026

 37,367

 $
 1.70

 12/16/2030

 9,167 3

 $
 2.07

 09/08/2033

 Options continue to vest ratably over the remaining thirty-six months of continuous service.

 Options are performance based and vest upon the achievement of clinical milestones as defined in Mr. Salva's employment agreement.

 25% of the option awards vest on the first anniversary of the grant date with the remaining shares vesting ratably each month during
the remaining thirty-six months of continuous service.

 Non-Employee
Director Compensation

 On
September 8, 2023, we granted to Barbara Ryan and John Schroer each an option to purchase up to 10,000 shares of our common stock at
an exercise price of $2.07 per share under the 2016 Plan. The options are subject to time-based vesting, with options to purchase 2,500
shares (25%) vesting on the first anniversary of the grant and options to purchase 7,500 shares (75%) vesting in equal monthly installments
over the 36 months following the first anniversary, subject t their continued service on our board of directors; The options expire on
the ten-year anniversary of the date of grant.

 Other
than the options described above, we have not paid any directors' fees or other compensation to our directors for their services
as directors. All of our directors receive reimbursement for out-of-pocket expenses for attending board of directors meetings. We intend
to commence the payment of our non-executive directors, including the payment of cash and equity awards, or a combination of both, but
we have not adopted any such plans or policies as of this date. From time to time, we may also engage certain outside members of the
board of directors to perform services on our behalf and we will compensate such persons for the services which they perform.

 Stock
Incentive Plans

 We
have adopted the Azitra, Inc. 2016 Stock Incentive Plan, or 2016 Plan, providing for the grant of non-qualified stock options and incentive
stock options to purchase shares of our common stock and for the grant of restricted and unrestricted share grants and restricted stock
units. We currently have reserved 242,345 shares of our common stock under the 2016 Plan. The purpose of the 2016 Plan is to provide
eligible participants with an opportunity to acquire an ownership interest in our company. All officers, directors, employees and consultants
to our company are eligible to participate under the 2016 Plan. The 2016 Plan provides that options may not be granted at an exercise
price less than the fair market value of our shares of common stock on the date of grant. As of the date of this report, we have outstanding
options granted under the 2016 Plan to purchase an aggregate of 1,248,255 shares of our common stock at an average exercise price of
$1.34 per share.

 In
March 2023, our Board and stockholders approved and adopted the Azitra, Inc. 2023 Stock Incentive Plan, or 2023 Plan, providing for the
grant of non-qualified stock options and incentive stock options to purchase shares of our common stock and for the grant of restricted
and unrestricted share grants and restricted stock units. We currently have reserved 2,000,000 shares of our common stock under the 2023
Plan. The purpose of the 2023 Plan is to provide eligible participants with an opportunity to acquire an ownership interest in our company.
All officers, directors, employees and consultants to our company are eligible to participate under the 2023 Plan. The 2023 Plan provides
that options may not be granted at an exercise price less than the fair market value of our shares of common stock on the date of grant.
As of the date of this report, we have outstanding options granted under the 2023 Plan to purchase an aggregate of 40,000 shares of our
common stock at an average exercise price of $2.07 per share.

 Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 The
following table sets forth certain information regarding the beneficial ownership of our shares of common stock as of the date of this
report by:

 each
 person who is known by us to be the beneficial owner of more than five percent (5%) of our issued and outstanding shares of common
 stock;

 each
 of our executive officers and directors; and

 all
 of the aforementioned directors and executive officers as a group.

 The
beneficial ownership of each person was calculated based on 28,804,643 shares of common stock issued as of March 31, 2024. The SEC has
defined "beneficial ownership" to mean more than ownership in the usual sense. For example, a person has beneficial ownership
of a share not only if he owns it, but also if he has the power (solely or shared) to vote, sell or otherwise dispose of the share. Beneficial
ownership also includes the number of shares that a person has the right to acquire within 60 days of March 31, 2024, pursuant to the
exercise of options or warrants or the conversion of notes, debentures or other indebtedness. Two or more persons might count as beneficial
owners of the same share.

 Unless
otherwise indicated, the address for each reporting person is c/o Azitra, Inc., 21 Business Park Drive, Branford, Connecticut 06405.

 Name of Director and Executive Officer

 Number of Shares

 Percentage Owned

 Francisco D. Salva (1)

 625,516

 2.2
 %

 Norman Staskey

 51,100

 *

 Travis Whitfill (2)

 427,653

 1.5
 %

 Andrew McClary (3)

 313,712

 1.1
 %

 Barbara Ryan

 —

 *

 John Schroer

 —

 *

 Directors and executive officers, as a group (6 persons)

 1,417,991

 4.9
 %

 Name and Address of Five Percent Stockholders

 Number of Shares

 Percentage Owned

 Bios Equity Entities (4)

 6,799,021

 23.5
 %

 *

 Represents
 less than 1% of the number of shares of our common stock outstanding.

 (1)

 Includes
 287,216 shares of our common stock issuable upon exercise of presently exercisable options.

 (2)

 Includes
 93,152 shares issuable upon exercise of presently exercisable options.

 (3)

 The
 securities are held by KdT Ventures LP, of which Mr. McClary is the managing partner. Includes 21,802 shares of our common stock
 issuable upon the exercise of warrants.

 (4)

 Consists
 of (i) 799,467 shares of common stock held by Bios Fund I, LP, (ii) 436,173 shares of common stock and 39,760 shares of common stock
 issuable upon the exercise of warrants held by Bios Azitra Co-Invest I, LP, (iii) 313,250 shares of common stock and 22,726 shares
 of common stock issuable upon the exercise of warrants held by Bios Fund II, LP, (iv) 404,767 shares of common stock held by Bios
 Fund III, LP, (v) 467,613 shares of common stock held by Bios Fund I QP, LP, (vi) 1,023,442 shares of common stock and 74,236 shares
 of common stock issuable upon the exercise of warrants held by Bios Fund II QP, LP, (vii) 2,643,705 shares of common stock held by
 Bios Fund III QP, LP, (viii) 137,000 shares of common stock and 9,938 shares of common stock issuable upon the exercise of warrants
 held by Bios Fund II NT, LP, (ix) 426,944 shares of common stock held by Bios Fund III NT, LP. Bios Equity Partners, LP is the general
 partner of the following entities: Bios Fund I, LP and Bios Fund I QP, LP. Bios Equity Partners II, LP is the general partner of
 Bios Fund II, LP, QP, LP, Bios Fund II, LP and Bios Fund II NT, LP. Cavu Management, LP, an entity managed and controlled by Mr.
 Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios
 Equity I, LP and Bios Equity II, LP. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner
 of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of
 Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and
 Bios Fund III NT ("Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis
 and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities. Travis Whitfill, a
 chief operator officer and director of the Company, was a partner at Bios Equity Partners, LP until June 2023, but did not have any
 voting or investment control with respect to the shares held by the Bio Equity Entities. The address for Bios Equity Entities is
 1751 River Run, Suite 400, Fort Worth, Texas 76107.

 Item
13. Certain Relationships and Related Transactions, and Director Independence

 Related
Party Transactions

 Except
as set forth below, since January 1, 2020, we have not been a party to any transaction in which the amount involved in the transaction
exceeded the lesser of $120,000 or one percent of the average of our total assets as of December 31, 2022 and 2021, and in which any
of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our voting securities or any member of
the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than compensation
arrangements, which include equity and other compensation, termination, change in control and other arrangements, which are described
under " Executive Compensation." We have adopted a policy that any transactions with directors, officers, beneficial
owners of five percent or more of our common stock, any immediate family members of the foregoing or entities of which any of the foregoing
are also officers or directors or in which they have a financial interest, will only be on terms consistent with industry standards and
approved by a majority of the disinterested directors of our Board.

 In
September 2022, we issued unsecured convertible promissory notes in the aggregate principal amount of $4.35 million to five existing
stockholders, including notes in the aggregate principal amount of $4 million to three funds under common control, namely Bios Fund III,
LP, Bios Fund III QP, LP, and Bios Fund III NT, LP. The Bios entities beneficially own a collective 6,799,021 shares, or approximately
23.5%, of our outstanding common stock as of the date of this report. In connection the Bios entities investment in our Company, we granted
the Bios entities certain board appointment rights pursuant to which they appointed to our Board a Bios representative who served on
our Board from April 2016 to the date preceding the date of our June 2023 IPO. In addition, Travis Whitfill, our co-founder, chief operating
officer and a member of our Board, was a partner of Bios Equity Partners, LP, the general partner of the aforementioned Bios entities,
until June 2023.

 In
December 2019, we entered into a Joint Development Agreement, or JDA, with Bayer pursuant to which we agreed to the joint development
of certain strains selected from our proprietary microbial library. Bayer paid us a one-time low six figure payment upon execution of
the JDA. Pursuant to the JDA, Bayer is responsible for reimbursing us for our development costs, and in 2023 Bayer has paid us a six-figure
dollar amount for our development costs. We have granted Bayer an option to acquire an exclusive royalty bearing license for up to six
(6) strains subject to development activities under the JDA, including an exclusive royalty bearing license to any related patent rights.

 In
September 2020, Bayer's venture capital group, LEAPS by Bayer, purchased $8 million of our Series B preferred stock. In connection
with the investment, we granted Bayer certain board appointment rights pursuant to which they appointed to our Board a Bayer representative
who served on our Board from September 2020 to the date preceding our IPO.

 Indemnification
Agreements

 We
have entered into indemnification agreements with each of our directors and executive officers that may be broader than the specific
indemnification provisions contained in the DGCL. These indemnification agreements require us, among other things, to indemnify our directors
and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also
require us to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit,
or proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive
officers.

 Director
Independence

 Our
Board may establish the authorized number of directors from time to time by resolution. Our Board currently consists of five (5) authorized
members. Generally, under the listing requirements and rules of the NYSE American, independent directors must comprise a majority of
a listed company's board of directors. Our Board has undertaken a review of its composition, the composition of its committees
and the independence of each director. Our Board has determined that, other than Mr. Salva and Mr. Whitfill, by virtue of their executive
officer positions, none of our director has a relationship that would interfere with the exercise of independent judgment in carrying
out the responsibilities of a director and that each is "independent" as that term is defined under the applicable rules
and regulations of the SEC and the listing requirements and rules of the NYSE American. In making this determination, our Board considered
the current and prior relationships that each nonemployee director nominee has with our Company and all other facts and circumstances
our Board deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each nonemployee
director nominee. Accordingly, a majority of our directors are independent, as required under applicable NYSE American rules, as of the
date of this report.

 Item
14. Principal Accountant Fees and Services

 Fees
Incurred for Services by Principal Accountant

 The
following table sets forth the aggregate fees billed to us for services rendered to us for the years ended December 31, 2023 and 2022
by our independent registered public accounting firm, Grassi & Co., CPAs, P.C. (in thousands).

 2023

 2022

 Audit Fees (A)

 $
 195,929

 $
 226,050

 Audit - Related Fees

 –

 –

 Tax Fees

 –

 –

 $
 195,929

 $
 226,050

 (A)

 The
 audit fees consisted of fees for the audit of our financial statements, the review of the interim financial statements included in
 our quarterly reports on Form 10-Q, and other professional services provided in connection with the statutory and regulatory filings
 or engagements and capital market financings.

 Pre-Approval
Policies and Procedures

 The
Audit Committee has responsibility for selecting, appointing, evaluating, compensating, retaining and overseeing the work of the independent
registered public accounting firm. In recognition of this responsibility, the Audit Committee has established policies and procedures
in its charter regarding pre-approval of any audit and non-audit service provided to the Company by the independent registered public
accounting firm and the fees and terms thereof.

 The
Audit Committee considered the compatibility of the provision of other services by its registered public accountant with the maintenance
of their independence. The Audit Committee approved all audit services provided by Grassi & Co. in 2023 and 2022. Grassi & Co.
did not perform any non-audit or tax services in 2023 or 2022.

 PART
IV

 Item
15. Exhibits and Financial Statement Schedules

 (c)
Exhibits

 The
exhibits to this Amendment No. 1 to Annual Report on Form 10-K/A are set forth below. The exhibit index indicates each management contract
or compensatory plan or arrangement required to be filed as an exhibit.

 Number

 Exhibit
 Description

 Method
 of Filing

 3.1

 Second Amended and Restated Certificate of Incorporation of the Registrant

 herein by reference to the Company's Current Report on Form 8-K filed on June 21, 2023.

 3.2

 Second Amended and Restated Bylaws of the Registrant

 herein by reference to the Company's Current Report on Form 8-K filed on June 21, 2023.

 4.1

 Specimen Certificate representing shares of Common Stock

 4.2

 Form of Warrant issued to Private Placement investors

 4.3

 Form of Representative's Warrant dated June 20, 2023 issued to ThinkEquity LLC

 4.4

 Form of Representative's Warrant dated February 16, 2024 issued to ThinkEquity LLC (attached to Underwriting Agreement between the Registrant and ThinkEquity, LLC dated February 13, 2024)

 herein by reference to the Company's Current Report on Form 8-K filed on February 14, 2024.

 4.5

 Description of Capital Stock

 herein by reference to the Company's Annual Report on Form 10-K filed on March 15, 2024

 10.1+

 Azitra Inc. 2016 Stock Incentive Plan

 10.2+

 Azitra Inc. 2023 Stock Incentive Plan

 10.3+

 Executive Employment Agreement dated April 22, 2021 between the Registrant and Francisco D. Salva

 10.4+

 Executive Employment Agreement dated July 5, 2023 between the Registrant and Travis Whitfill

 herein by reference to the Company's Form S-1 filed on January 19, 2024.

 10.5+

 Form of Indemnity Agreement between the Registrant and each of its directors and executive officers

 10.6

 Second Amended and Restated Investors' Rights Agreement dated September 10, 2020 between the Registrant and each of the investors named therein

 21.1

 List of Subsidiaries of the Registrant

 herein by reference to the Company's Form S-1 filed on March 20, 2023.

 31.1

 Certification under Section 302 of the Sarbanes-Oxley Act of 2002

 Filed
 electronically herewith.

 31.2

 Certification under Section 302 of the Sarbanes-Oxley Act of 2002

 Filed
 electronically herewith.

 32.1

 Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

 Furnished
 as part of the Company's Annual Report on Form 10-K filed on March 15, 2024.

 97.1

 Azitra, Inc. Executive Officer Clawback Policy

 herein by reference to the Company's Annual Report on Form 10-K filed on March 15, 2024.

 +

 Indicates
 management compensatory plan, contract or arrangement.

 Item
16. Form 10-K Summary

 Not
provided.

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment No.
1 to Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.

 AZITRA,
 INC.

 Date:
 April 29, 2024

 By:

 /s/
 Francisco D. Salva

 D. Salva,

 Chief
 Executive Officer and Director